Overview

A Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male Volunteers

Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The study aims to understand, using radiolabelled PF-06463922, how this compound is modified by the body once it is absorbed. The study also aims to understand how much of the compound is broken down and how much leaves the body unchanged.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer